

Yervoy[®] (ipilimumab)

Patient Alert Card

For further information, consult the Yervoy Patient Information Leaflet (PIL) at <http://www.medicines.org.uk/emc> or Bristol-Myers Squibb Medical Information on 0800 731 1736.

Date of Preparation: August 2018 731UK1800900-01



Bristol-Myers Squibb

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

By reporting side effects you can help provide more information on the safety of this medicine.

Yervoy (ipilimumab)

This card has important information on the use of **ipilimumab alone** for the treatment of advanced melanoma.

Always carry this alert card with you and show it to any doctor you may need to see (for example, if your regular doctor is unavailable or you are travelling). It is important that you keep this card for at least 6 months after completing your treatment.



Tell your Doctor right away if you have any of these symptoms or any other symptoms.

BOWEL AND STOMACH¹

- diarrhoea (watery, loose or soft stools), bloody or darker-coloured stools
- more frequent bowel movements than usual
- pain or tenderness in your stomach or abdomen area, nausea, vomiting

LIVER¹

- eye or skin yellowing (jaundice)
- pain on the right side of your stomach area
- dark urine

SKIN¹

- skin rash with or without itching, dry skin
- blisters and/or peeling of the skin, mouth sores
- swelling of the face or lymph glands

EYE¹

- redness in the eye
- pain in the eye
- vision problems or blurry vision

NERVES¹

- muscle weakness
- numbness or tingling in legs, arms, or face
- dizziness, loss of consciousness or difficulty waking up

GENERAL¹

- fever, headaches, tiredness
- bleeding
- behavioural changes (e.g. less sex drive, being irritable or forgetful)

IMPORTANT INFORMATION

- Report any of these symptoms to your doctor right away.
- Symptoms that may appear mild can quickly worsen if left untreated.¹
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped, allowing you to potentially get the maximum benefit from treatment.
- Signs and symptoms may be delayed and may occur weeks to months after your last injection.¹
- Don't try to treat these symptoms yourself without consulting with your doctor first.
- Carry this Patient Alert Card and show it to any doctor you might interact with, and say that you are being treated with ipilimumab.

You can get more information in the Yervoy Patient Information Leaflet: <http://www.medicines.org.uk/emc> and at the following website address: <http://pwa.ltd/yervoy-pat-uk>

My physician's contact information

Name of Physician

.....
.....

Office Phone

.....
.....

After-hours Phone

.....
.....

My Name and Phone

.....
.....

Name and contact number of Caregiver
(in case of emergency)

.....
.....

IMPORTANT information for healthcare providers

- This patient is treated with Yervoy monotherapy.
- Immune-related Adverse Reactions (irARs), can mostly occur during the treatment period, but may appear months after the last dose of Yervoy.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications. Yervoy specific management guidelines for irARs are available.
- If you are a doctor not specialised in oncology, please contact a specialist.

Healthcare providers please consult the Yervoy Summary of Product Characteristics and/or Yervoy Risk Minimisation Information for Healthcare Professionals Guide for Prescribing at <http://www.medicines.org.uk/emc> or call Bristol-Myers Squibb Medical Information department (telephone 0800 731 1736; email medical.information@bms.com) for more information.

1. Yervoy Patient Information Leaflet

HEAD
FRONT COVER
FOOT

HEAD
BACK COVER
FOOT